Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study
This study firstly supplements real-world evidence on T-DXd treatment in Chinese patients with previously treated <i>HER2</i>-mutant advanced NSCLC. The results preliminarily showed the favorable antitumor activity and acceptable safety profile of T-DXd in clinical practice.
Authors
- Xianghua Wu
- Jialin QIAN
- Zhihuang Hu (ORCID: https://orcid.org/0000-0002-6547-3832)
- Huishu Dong
- Jialei Wang (ORCID: https://orcid.org/0000-0001-9977-2219)
- Kuofang Huang
- Huijie Wang (ORCID: https://orcid.org/0000-0002-1451-5158)
- Haijiao Lu
- Shifei Pan
- Kai Wang
Institutions
- Shanghai Medical College of Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Shanghai Chest Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai Cancer Institute (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tlcr-2025-916
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00